You have 9 free searches left this month | for more free features.

EGFr

Showing 1 - 25 of 5,630

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Nintedanib, gefitinib, erlotinib, afatinib
  • (no location specified)
Oct 2, 2023

Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant

Completed
  • The Primary Study Metric is Progression-free Survival (PFS)
    • (no location specified)
    Jun 28, 2023

    EGFR Mutant Advanced NSCLC Trial (BBT-207)

    Not yet recruiting
    • EGFR Mutant Advanced Non-Small Cell Lung Cancer
    • (no location specified)
    Jun 16, 2023

    NSCLC Trial in Singapore (Afatinib 40 MG)

    Not yet recruiting
    • NSCLC
    • Afatinib 40 MG
    • Singapore, Singapore
      National University Hospital
    Sep 25, 2023

    IASLC Grading System as a Predictor for EGFR-TKI Therapy

    Completed
    • Lung Cancer
    • IASLC grading system
    • Shanghai, Please Select, China
      Chaoqiang Deng
    Nov 9, 2023

    Solid Tumor, EGFR Amplification Trial in Tianjin (Nimotuzumab)

    Recruiting
    • Solid Tumor
    • EGFR Amplification
    • Tianjin, Tianjin, China
      Tianjin Medical University Second Hospital
    Aug 28, 2023

    NSCLC Trial in Shanghai (IN10018, Furmonertinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 8, 2023

    Lung Cancer Trial in Boston, Nashville

    Active, not recruiting
    • Lung Cancer
      • Boston, Massachusetts
      • +1 more
      Dec 28, 2022

      Cancer, Solid Tumor, Colorectal Cancer Trial (biological, radiation, drug)

      Not yet recruiting
      • Cancer
      • +8 more
      • DK210 (EGFR)
      • +3 more
      • (no location specified)
      Jan 27, 2023

      Brain Metastases, NSCLC Trial in Shanghai (EGFR-TK Inhibitor, Stereotactic radiotherapy)

      Recruiting
      • Brain Metastases
      • Non-small Cell Lung Cancer
      • EGFR-TK Inhibitor
      • Stereotactic radiotherapy
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Aug 27, 2023

      NSCLC Trial in Changsha (BEBT-109)

      Completed
      • NSCLC
      • Changsha, Hunan, China
        Hunan Cancer hospital
      Aug 20, 2023

      Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

      Recruiting
      • Nasopharyngeal Carcinoma
      • Anti-EGFR and PD-1 inhibitor arm
      • Shanghai, Shanghai, China
        Eye & ENT Hospital of Fudan University
      Nov 26, 2023

      Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

      Not yet recruiting
      • Non Squamous Non Small Cell Lung Cancer
      • EGFR Positive Non-small Cell Lung Cancer
      • Toripalimab plus Chemotherapy
      • (no location specified)
      Jul 28, 2023

      EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy

      Not yet recruiting
      • EGF-R Positive Non-Small Cell Lung Cancer
      • +4 more
      • Stereotactic Body Radiation Therapy SBRT
      • Bogotá, Colombia
        CTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
      Aug 16, 2023

      NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

      Recruiting
      • NSCLC
      • EGFR Gene Mutation
      • neo-antigen vaccine
      • Nanjing, China
        The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
      Oct 19, 2023

      NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

      Not yet recruiting
      • NSCLC
      • +2 more
      • Beijing, Beijing, China
        National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
      Jul 9, 2023

      Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

      Not yet recruiting
      • Lung Cancer
      • +4 more
      • (no location specified)
      Sep 15, 2023

      NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100

      Not yet recruiting
      • Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
      • MCLA-129: 1500mg or 2000mg IV Q2W
      • Befotertinib: 75 mg or 100 mg Po QD
      • Bengbu, Anhui, China
      • +2 more
      Aug 28, 2023

      Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

      Recruiting
      • Non-small Cell Lung Cancer
        • Guanzhou, China
          Sun Yat-sen University Cancer Center
        Aug 11, 2023

        CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)

        Active, not recruiting
        • Central Nervous System Tumor, Pediatric
        • +8 more
        • EGFR806-specific chimeric antigen receptor (CAR) T cell
        • Seattle, Washington
          Seattle Children's Hospital
        Jan 18, 2023

        Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

        Not yet recruiting
        • Aumolertinib
        • +4 more
        • (no location specified)
        Mar 8, 2023

        NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • (no location specified)
        May 23, 2023

        NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

        Not yet recruiting
        • Non-Small Cell Lung Cancer
        • +2 more
        • Fairfax, Virginia
          NEXT Virginia
        Sep 18, 2023

        Brain Metastases, Radiotherapy, EGFR Activating Mutation Trial in Guangdong (brain radiotherapy, Almonertinib)

        Recruiting
        • Brain Metastases
        • +2 more
        • Guangdong, Guangzhou, China
          Sun-Yat-Sen university
        Mar 13, 2023

        Lung Cancer Stage III Trial (Almonertinib)

        Not yet recruiting
        • Lung Cancer Stage III
        • (no location specified)
        Aug 8, 2023